2019 – Publications

Converse PJ, Almeida DV, Tyagi S, Xu J, Nuermberger EL. Shortening Buruli ulcer treatment with combination therapy targeting the respiratory chain and exploiting M. ulcerans gene decay. Antimicrob Agents Chemother. 2019;63(7):e00426-19. doi: 10.1128/AAC.00426-19. PMID: 31036687.

Xu J, Li SY, Almeida DV, Tasneen R, Barnes-Boyle K, Converse PJ, Upton AM, Mdluli K, Fotouhi N, Nuermberger EL. Contribution of pretomanid to novel regimens containing bedaquiline with either linezolid or moxifloxacin and pyrazinamide in murine models of tuberculosis. Antimicrob Agents Chemother. 2019;63(5): e00021-19. doi: 10.1128/AAC.00021-19. PMID: 30833432.

Kaushik A, Ammerman NC, Martins O, Parrish NM, Nuermberger EL. In vitro activity of new tetracycline analogs omadacycline and eravacycline against drug-resistant clinical isolates of Mycobacterium abscessus. Antimicrob Agents Chemother. 2019. doi: 10.1128/AAC.00470-19. PMID: 30962331.

Saini V, Ammerman NC, Chang YS, Tasneen R, Chaisson RE, Jain S, Nuermberger E, Grosset JH. Treatment-shortening effect of a novel regimen combining high-dose rifapentine and clofazimine in pathologically distinct mouse models of tuberculosis. Antimicrob Agents Chemother. 2019. doi: 10.1128/AAC.00388-19. PMID: 30936097.

Kaushik A, Ammerman NC, Tyagi S, Saini V, Vervoort I, Lachau-Durand S, Nuermberger E, Andries K. Activity of a long-acting injectable bedaquiline formulation in a paucibacillary mouse model of latent tuberculosis infection. Antimicrob Agents Chemother. 2019;63(4): e00007-19. doi: 10.1128/AAC.00007-19. PMID: 30745396.

Kaushik A, Ammerman NC, Lee J, Martins O, Kreiswirth BN, Lamichhane G, Parrish NM, Nuermberger EL. In vitro activity of the new β-lactamase inhibitors relebactam and vaborbactam in combination with β-lactams against Mycobacterium abscessus complex clinical isolates Antimicrob Agents Chemother. 2019;63(3): e02623-18. doi: 10.1128/AAC.02623-18. PMID: 30642943.

Almeida DV, Omansen TF, Li SY, Lee J, Grosset JH, Converse PJ, Nuermberger EL. Oxazolidinones can replace clarithromycin in combination with rifampin in a mouse model of Buruli ulcer. Antimicrob Agents Chemother. 2019;63(3): e02171-18. doi: 10.1128/AAC.02171-18. PMID: 30559131.

Omansen TF, Almeida D, Converse PJ, Li SY, Lee J, Stienstra Y, van der Werf T, Grosset JH, Nuermberger EL. High-dose rifamycins enable shorter oral treatment in a murine model of Mycobacterium ulcerans disease. Antimicrob Agents Chemother. 2019;63(2): e01478-18. doi: 10.1128/AAC.01478-18. PMID: 30455239.

Kaushik A, Ammerman NC, Parrish NM, Nuermberger EL.New β-Lactamase Inhibitors Nacubactam and Zidebactam Improve the In Vitro Activity of β-Lactam Antibiotics Against Mycobacterium abscessus Complex Clinical Isolates. Antimicrob Agents Chemother. 2019: AAC.00733-19. doi: 10.1128/AAC.00733-19. PMID: 31209013.